Nikolaus McFarland
CLIN PROF
MD-NEUROLOGY
GRANTS
- GRANTCUREPSP CoC 2026-2027Cure Psp Foundation23 Jun 2026 - 30 Jun 2027
- GRANTA Phase 2, Randomized, Double-Blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s DiseaseAskbio Inc14 May 2026 - 13 May 2031
- GRANT2026 UF MSA Center of ExcellenceMultiple System Atrophy Coalition27 Feb 2026 - 31 Dec 2027
- GRANTHDSA 2025 extension on PRO00064796/AWD18562Huntingtons Disease Society of America20 Feb 2026 - 31 Dec 2026
- GRANTPhase 2/3 Randomized, Double- Blind, Placebo Controlled Study of BHV-8000 in Participants with Early Perkinson’s Disease (“Protocol”).Biohaven Pharmaceuticals3 Nov 2025 - 2 Nov 2030
- GRANTCurePSP Centers of Care 2025-2026Cure Psp Foundation3 Jul 2025 - 30 Jun 2026
- GRANTHDSA Center of Excellence 2025: University of Florida, Fixel Institute for Neurological DiseasesHuntingtons Disease Society of America7 May 2025 - 31 Dec 2025
- GRANTInterventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy”, number: 20432AH. Lundbeck A/S4 Mar 2025 - 3 Mar 2030
- GRANTUF MSA Center of ExcellenceMultiple System Atrophy Coalition27 Jan 2025 - 31 Dec 2025
- GRANTThe Parkinson’s Progression Markers Initiative (PPMI) Clinical - Establishing a Deeply Phenotyped PD CohortFox Foundation, Michael J14 Oct 2024 - 14 Apr 2025
- GRANTPridopidine Post Trial Access Protocol in Patients with Huntington's Disease. (“PTAP”)Prilenia Therapeutics11 Sep 2024 - 10 Sep 2029
- GRANTA35-009, A Phase 2b/3 Study of Safety and Efficacy of AMX0035 in Progressive Supranuclear Palsy (ORION)Amylyx Pharmaceuticals16 Jul 2024 - 22 Oct 2025
- GRANTCurePSP Centers of Care 2024-2025Cure Psp Foundation1 Jul 2024 - 30 Jun 2025
- GRANTHDSA Center of Excellence 2024: University of Florida, Fixel Institute for Neurological DiseasesHuntingtons Disease Society of America20 Feb 2024 - 31 Dec 2024
- GRANTA Phase 2, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential efficacy of multiple doses of ONO-2808 in patients with Multiple System Atrophy (MSA)Ono Pharmaceutical24 Jan 2024 - 23 Jan 2029
- GRANTUF MSA Center of ExcellenceMultiple System Atrophy Coalition6 Nov 2023 - 5 Nov 2024
- GRANTFY24 CurePSP Center of Care AwardCure Psp Foundation27 Jun 2023 - 30 Jun 2024
- GRANTA Randomized, Double-blind, Placebo-controlled Study of ATH434 in Multiple System AtrophyAlterity Therapeutics1 Jun 2023 - 16 Apr 2024
- GRANTHDSA Center of Excellence 2023 Award: University of FloridaHuntingtons Disease Society of America23 Feb 2023 - 31 Dec 2023
- GRANTA Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Huntington's DiseaseGenentech Inc22 Feb 2023 - 7 Feb 2028
- GRANT214 Fund - CTOA McFarland CT SalaryUniversity of Florida25 May 2022 - 24 May 2027
- GRANTCure PSP Center of CareCure Psp Foundation16 May 2022 - 31 Mar 2023
- GRANTA Natural History Study of Clinical, MRI and biofluid biomarkers in patients with Early MSA biomarkers of Progression in MUltiple SystEms Atrophy (bioMUSE)Alterity Therapeutics3 May 2022 - 14 Apr 2023
- GRANTReal-World Utilization of Deutetrabenazine Initiated by a 4-week Patient Titration KitTeva Branded Pharmaceuticals Prod R&D12 Apr 2022 - 22 Jun 2024
- GRANTInterventional, randomized, double-blind, parallel-group, placebo-controlled, multi-centre study to assess the efficacy, safety and tolerability of Lu AF82422 in patients with Multiple System AtrophyH. Lundbeck A/S10 Mar 2022 - 3 Feb 2026